NASDAQ, TELK - Telik
Telik, Inc. was incorporated in Delaware in 1988 and is a biopharmaceutical
company working to discover, develop and commercialize innovative small molecule
drugs to treat diseases. We discovered our product candidates using our
proprietary drug discovery technology, Target-Related Affinity Profiling, or
TRAP, which we believe enables the rapid and efficient discovery of small
molecule product candidates. To date, we have not obtained regulatory approval
for the commercial sale of any products, and we have not received any revenue
from the commercial sale of products.
TELCYTA, our lead product candidate, is a small molecule cancer drug product
candidate designed to be activated in cancer cells. The product candidate binds
to glutathione S-transferase P1-1, or GST P1-1, a protein that is elevated in
many human cancers, such as ovarian, non-small cell lung, colorectal, breast and
other types of cancer. ...
Read SEC Filing on NASDAQ.com »